Common pathways of depression and pain

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 12, 2004, Pages 16-19

  Delgado, Pedro L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; DULOXETINE; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE; VENLAFAXINE;

BRAIN; CHRONIC DISEASE; DEGENERATIVE DISEASE; DEPRESSION; DIABETIC NEUROPATHY; DRUG EFFECT; HUMAN; NERVE CELL; NERVE CELL PLASTICITY; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; RECURRENT DISEASE; REVIEW;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; BRAIN; CHRONIC DISEASE; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DIABETIC NEUROPATHIES; HUMANS; NEURODEGENERATIVE DISEASES; NEURONAL PLASTICITY; NEURONS; NOREPINEPHRINE; PAIN; RECURRENCE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 4644255535     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Kellner R, Sheffield BF. The one-week prevalence of symptoms in neurotic patients and normals. Am J Psychiatry 1973;130:102-105
2. Silverstein B. Gender difference in the prevalence of somatic versus pure depression: a replication. Am J Psychiatry 2002;159:1051-1052
3. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998;44:348-360
4. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149:795-800
5. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
6. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
7. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
8. Angst J. How recurrent and predictable is depressive illness? In: Montgomery SA, Rouillon F, eds. Long-Term Treatment of Depressive Perspectives in Psychiatry, vol 3. Chichester, England: Wiley; 1992:1-13
9. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(5, suppl):28-34
10. Georgotas A, McCue RE. Relapse of depressed patients after effective continuation therapy. J Affect Disord 1989;17:159-164
11. Steffens DC, Byrum CE, McQuoid DR, et al. Hippocampal volume in geriatric depression. Biol Psychiatry 2000;48:301-309
12. Mervaala E, Fohr J, Kononen M, et al. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med 2000;30:117-125
13. Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000;157:115-117
14. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent depression. J Neurosci 1999;19:5034-5043
15. Sheline YI, Wang PO, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996;93:3908-3913
16. Frodl T, Meisenzahl EM, Zetzsche T, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 2002;159:1112-1118
17. Stahl SM. The psychopharmacology of painful physical symptoms in depression [BRAINSTORMS]. J Clin Psychiatry 2002;63:382-383
18. Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001;26:37-43
19. Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 1997;11(suppl 4):S25-S31
20. Santarelli L, Saxe MD, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809
21. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999;46:212-220
22. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418
23. Delgado PL, Price LH, Miller HL, et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991;27:321-330
24. Delgado PO, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-396
25. Miller JL, Delgado PL, Salomon RM, et al. Effects of alpha-methyl- paratyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology 1996;14:151-157
26. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-128
27. Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry 2000;61(suppl 1):5-12
28. Iyengar S, Bymaster F, Wong D, et al. Efficacy of the selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain [abstract]. Pain Med 2002:3:177
29. Kunz NR, Goli V, Entsuah R, et al. Diabetic neuropathic pain management with venlafaxine extended release [abstract]. Eur Neuropsychopharmacol 2000;10(suppl 3):S389
30. Goldstein DJ, Lu Y, Iyengar S, et al. Duloxetine in the treatment of the pain associated with diabetic neuropathy. In: New Research Abstracts of the 156th annual meeting of the American Psychiatric Association; May 19, 2003; San Francisco, Calif. Abstract NR185:68-69